Serotonin model of schizophrenia: emerging role of glutamate mechanisms

Brain Research Reviews

Volumn 31, Issue 2-3, 2000, Pages 302-312

  Aghajanian, George K ^a   Marek, Gerard J ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

5 HT(2A) receptor; Hallucinogen; Ketamine; Locus coeruleus; LSD; Metabotropic receptor; NMDA receptor; Phencylidine; Prefrontal cortex

Indexed keywords

1 AMINO 1,3 CYCLOPENTANEDICARBOXYLIC ACID; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMPA RECEPTOR ANTAGONIST; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; INDOLEAMINE; KAINIC ACID RECEPTOR ANTAGONIST; KETAMINE; LYSERGIDE; MESCALINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PHENETHYLAMINE; PSYCHEDELIC AGENT; SEROTONIN; SEROTONIN 2A RECEPTOR;

BRAIN CORTEX; BRAIN REGION; CONFERENCE PAPER; EXCITATORY POSTSYNAPTIC POTENTIAL; HUMAN; HYPOTHESIS; LOCUS CERULEUS; MEMBRANE CURRENT; MODEL; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; POSTSYNAPTIC MEMBRANE; PREFRONTAL CORTEX; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

ANIMALS; BRAIN; GLUTAMIC ACID; HUMANS; RECEPTORS, GLUTAMATE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN;

EID: 0034055690     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(99)00046-6     Document Type: Conference Paper

References (90)

1. Abi-Saab W.M., D'Souza D.C., Moghaddam B., Krystal J.H. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry. 31(Suppl.):1998;104-109.
2. Aghajanian G.K. Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli. Brain Res. 186:1980;492-498.
3. G.K. Aghajanian, Electrophysiology of serotonin receptor subtypes and signal transduction mechanisms, in: F.E. Bloom and D.J. Kupfer (Eds.), Psychopharmacology: the Fourth Generation of Progress, Raven Press, New York, 1995, pp. 451-460.
4. Aghajanian G.K., Foote W.E., Sheard M.H. Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. Science. 161:1968;706-708.
5. Aghajanian G.K., Haigler H.J. Hallucinogenic indoleamines: preferential action upon presynaptic serotonin receptors. Psychopharmacology. 1:1975;619-629.
6. Aghajanian G.K., Haigler H.J., Bloom F.E. Lysergic acid diethylamide and serotonin: direct actions on serotonin-containing neurons in rat brain. Life Sci. 11:1972;615-622.
7. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology. 36:1997;589-599.
8. 2A receptors increase EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release, Brain Res. (1999) in press.
9. G.K. Aghajanian, G.J. Marek, Serotonin and hallucinogens, Neuropsychopharmacology (1999) in press.
10. Altar C.A., Wasley A.M., Neale R.F., Stone G.A. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res. Bull. 16:1986;517-525.
11. Andreasen N.C., O'Leary D.S., Flaun M., Nopoulos P., Watkins G.L., Boles Ponto L.L. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 349:1997;1730-1734.
12. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 40:1991;399-412.
13. R.C. Arora, H.Y. Meltzer, Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients, J. Neural. Transm. Gen. Sect. 85 (1991).
14. 2A receptor gene and response to clozapine. Mol. Psychiatry. 3:1998;61-66.
15. Aston-Jones G., Bloom F.E. Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J. Neurosci. 1:1981;887-900.
16. Axelrod J. Enzymatic formation of psychotomimetic metabolites from naturally occurring compounds. J. Pharmacol. Exp. Ther. 138:1962;28-33.
17. Balestrieri A., Fontanari D. Acquired and crossed tolerance to mescaline, LSD-25, and BOL-148. Arch. Gen. Psychiatry. 1:1959;279-282.
18. Bennett J.P., Enna S.J., Bylund D.B., Gillin J.C., Wyatt R.J., Snyder S.H. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psychiatry. 36:1979;927-934.
19. 2 receptors and serotonergic axons in rat neocortex. Brain Res. 453:1988;315-328.
20. Bonson K.R., Buckholtz J.W., Murphy D.L. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology. 14:1996;125-436.
21. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psychiatry. 154:1997;805-811.
22. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-445.
23. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
24. Carlsson A., Hansson L.O., Waters N., Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci. 61:1997;75-94.
25. 2A receptor antagonist MDL 100, 907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - implications for psychosis. J. Neural Transm. 100:1995;225-237.
26. Cedarbaum J.M., Aghajanian G.K. Activation of locus coeruleus neurons by peripheral stimuli: modulation by a collateral inhibitory mechanism. Life Sci. 23:1978;1383-1392.
27. Ceulemans D.L., Gelders Y.G., Hoppenbrouwers M.L., Reyntjens A.J., Janssen P.A. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology. 85:1985;329-332.
28. 2 agonist augments γ-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience. 54:1993;409-420.
29. Cleghorn J.M., Garnett E.S., Nahmias C., Firnau G., Brown G.M., Kaplan R., Szechtman H., Szechtman B. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res. 28:1989;119-133.
30. Dahlstrom A., Fuxe K. Evidence for the existence of monoamine containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. 62(Suppl. 232):1964;1-55.
31. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced metabolic activation. Brain Res. 812:1998;65-75.
32. 99mTc-exametazime in unmedicated schizophrenic patients. Biol. Psychiatry. 33:1993;487-495.
33. Freedman D.X. Effects of LSD-25 on brain serotonin. J. Pharmacol. Exp. Ther. 134:1961;160-166.
34. Gaddum J.H., Hammeed K.A. Drugs which antagonize 5-hydroxytryptamine. Br. J. Pharmacol. 9:1954;240-248.
35. Glennon R.A. Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology. 3:1990;509-517.
36. 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35:1984;2502-2511.
37. Goda Y., Stevens C.F. Two components of transmitter release at a central synapse. Proc. Natl. Acad. Sci. USA. 91:1994;12942-12946.
38. Gouzoulis-Mayfrank E., Hermle L., Thelen B., Sass H. History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry. 31(Suppl.):1998;63-68.
39. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry. 42:1997;529-545.
40. Haigler H.J., Aghajanian G.K. Mescaline and LSD: direct and indirect effects on serotonin-containing neurons in brain. Eur. J. Pharmacol. 21:1973;53-60.
41. Hamada S., Senzaki K., Hamaguchi-Hamada K., Tabuchi K., Yamamoto H., Yamamoto T., Yoshikawa S., Okano H., Okado N. Localization of 5-HT2A receptor in rat cerebral cortex and olfactory system revealed by immunohistochemistry using two antibodies raised in rabbit and chicken. Mol. Brain Res. 54:1998;199-211.
42. Haznedar M.M., Buchsbaum M.S., Luu C., Hazlett E.A., Siegel B.V., Lohr J., Wu J., Haier R.J., Bunney W.E.J. Decreased anterior cingulate gyrus metabolic rate in schizophrenia. Am. J. Psychiatry. 154:1997;682-684.
43. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 284:1998;651-660.
44. Hermle L., Funfgeld M., Oepen G., Botsch H., Borchardt D., Gouzoulis E., Fehrenbach R.A., Spitzer M. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol. Psychiatry. 32:1992;976-991.
45. Hoyer D., Clarke D.E., Fozard R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.A. VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Revs. 46:1994;157-203.
46. 2A serotonin receptors in the primate cerbral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. USA. 95:1998;735-740.
47. Jakab R.L., Leranth C. Catecholaminergic, GABAergic, and hippocamposeptal innervation of GABAergic 'somatospiny' neurons in the rat lateral septal area. J. Comp. Neurol. 302:1990;305-321.
48. Kroeze W.K., Roth G.L. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol. Psychiatry. 44:1998;1128-1142.
49. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 6:1995;869-872.
50. Laruelle M., Abi-Dargham A., Casanova M.F., Toti R., Weinberger D.R., Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A post-mortem study. Arch. Gen. Psychiatry. 50:1993;810-818.
51. 2+ binding properties of synaptotagmins. J. Biol. Chem. 270:1995;24898-24902.
52. Lindefors N., Barati S., O'Connor W.T. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res. 759:1997;205-212.
53. 3H ]MDL 100,907 Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;446-454.
54. 2A receptors on neurons in the rat piriform cortex. J. Pharmacol. Exp. Ther. 278:1996;1373-1382.
55. Marek G.J., Aghajanian G.K. 5-HT-induced EPSCs in neocortical layer V pyramidal cell of prefrontal cortex: Suppression by μ opiate receptor activation. Neuroscience. 86:1998;485-497.
56. 2A receptor-induced EPSCs in layer V pyramidal cells of prefrontal cortex: block by group II/III metabotropic glutamate agonists. Soc. Neurosci. Abs. 24:1998;1366.
57. 1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex, Eur. J. Pharmacol. (1999) in press.
58. P. Martin, M.L. Carlsson, S. Hjorth, Systemic PCP treatment elevated brain extracellular 5-HT: a microdialysis study, Neuroreport (1999) in press.
59. Martin P., Waters N., Schmidt C.J., Carlsson A., Carlsson M.L. Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone. J. Neural Transm. 105:1998;365-396.
60. Mathe J.M., Nomikos G.G., Schilstrom B., Svensson T.H. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J. Neurosci. Res. 51:1998;583-592.
61. Maurel-Remy S., Bervoets K., Millan M.J. Blockade of phencyclinine-induced hyperlocomotion by MDL 100,907. Eur. J. Pharmacol. 180:1995;R9-R11.
62. i values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
63. 2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res. 524:1990;139-143.
64. Mita T., Hanada S., Nishino N., Kuno T., Nakai T., Yamadori T., Mizoi Y., Tanaka C. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiatry. 21:1986;1407-1414.
65. Moghaddam B., Adams B. Stimulation of group II metabotropic glutamate receptors normalizes the cognitive and motoric effects of phencylidine. Science. 281:1998;1349-1352.
66. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with prefrontal cortex. J. Neurosci. 17:1997;2921-2927.
67. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
68. Osmond H., Smythies J.R. Schizophrenia: a new approach. J. Ment. Sci. 98:1952;309-315.
69. Parellada E., Catafau A.M., Bernardo M., Lomena F., Gonzalez-Monclus E., Setoain J. Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT study. Psychiatr. Res. Neuroimaging. 55:1994;131-139.
70. Pazos A., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 346:1985;205-230.
71. Pearlson G.D. Psychiatric and medical syndromes associated with phencyclidine (PC) abuse. John Hopkins Med. J. 148:1981;25-33.
72. 2 antagonists. Brain Res. 385:1986;395-400.
73. 2 binding affinity. Neuropsychopharmacology. 1:1988;101-107.
74. Resnick O., Krus D.M., Raskin M. LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor. Life Sci. 3:1964;1207-1214.
75. Sanders-Bush E., Burris K.D., Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J. Pharmacol. Exp. Therapeutics. 246:1988;924-928.
76. Schoepp D.D., Johnson B.G., Wright R.A., Salhoff C.R., Mayne N.G., Wu S., Cockerham S.L., Burnett J.P., Belegaje R., Bleakman D., Monn J.A. Ly354740 is a potent and highly selective Group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology. 36:1997;1-11.
77. Shaw E., Woolley D.W. Some serotonin-like activities of lysergic acid diethylamide. Science. 124:1956;121-123.
78. 2-activated interneuron. Brain Res. 506:1990;62-69.
79. Szara S. Dimethyltryptamine: its metabolism in man; the relation of its psychotic effect to serotonin metabolism. Experientia. 12:1956;441-442.
80. Tamminga C.A. Sertotonin and schizophrenia. Biol. Psychiatry. 44:1998;1079-1080.
81. Tanaka E., North R.A. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J. Neurophys. 69:1993;1749-1757.
82. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology. 94:1988;213-216.
83. 2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophrenia Res. 31:1998;13-17.
84. 18F ]fluorodeoxyglucose (FDG) Eur. Neuropsychopharmocol. 7:1997;9-24.
85. Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 16:1997;357-372.
86. Williams J., Spurlock G., McGuffin P., Mallet J., Nothen M.M., Gill M., Aschauer H., Nylander P.-O., Macciardi F., Owen M.J. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. Lancet. 347:1996;1294-1296.
87. 2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 27:1997;32-79.
88. Woolley D.W., Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. USA. 40:1954;228-231.
89. Woolley D.W., Shaw W. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. USA. 40:1954;228-231.
90. 2 receptors in reserpinized rats. Neuropharmacology. 26:1987;1489-1497.